ZA99940B - Chemical compounds. - Google Patents

Chemical compounds.

Info

Publication number
ZA99940B
ZA99940B ZA9900940A ZA99940A ZA99940B ZA 99940 B ZA99940 B ZA 99940B ZA 9900940 A ZA9900940 A ZA 9900940A ZA 99940 A ZA99940 A ZA 99940A ZA 99940 B ZA99940 B ZA 99940B
Authority
ZA
South Africa
Prior art keywords
optionally substituted
formula
pharmaceutically acceptable
range
organic groups
Prior art date
Application number
ZA9900940A
Other languages
English (en)
Inventor
Alan Wellington Faull
Andrew John Barker
Jason Grant Kettle
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of ZA99940B publication Critical patent/ZA99940B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA9900940A 1998-02-17 1999-02-05 Chemical compounds. ZA99940B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9803228.7A GB9803228D0 (en) 1998-02-17 1998-02-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ZA99940B true ZA99940B (en) 1999-08-17

Family

ID=10827056

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900940A ZA99940B (en) 1998-02-17 1999-02-05 Chemical compounds.

Country Status (16)

Country Link
US (1) US6479527B1 (enExample)
EP (1) EP1056451B1 (enExample)
JP (1) JP2002502874A (enExample)
KR (1) KR20010040997A (enExample)
CN (1) CN1291094A (enExample)
AT (1) ATE227570T1 (enExample)
AU (1) AU2432999A (enExample)
BR (1) BR9907936A (enExample)
CA (1) CA2319082A1 (enExample)
DE (1) DE69903923T2 (enExample)
GB (1) GB9803228D0 (enExample)
IL (1) IL137876A0 (enExample)
NO (1) NO20004091L (enExample)
NZ (1) NZ505638A (enExample)
WO (1) WO1999040914A1 (enExample)
ZA (1) ZA99940B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000626D0 (en) * 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
JP2005506949A (ja) 2000-12-20 2005-03-10 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体の調節剤としてのジアミン
AR035773A1 (es) 2000-12-20 2004-07-14 Bristol Myers Squibb Pharma Co Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
RU2004109818A (ru) * 2001-10-03 2005-05-10 Юсиби, С.А. (Be) Производные пирролидинона
PT1543011E (pt) 2002-09-06 2006-08-31 Janssen Pharmaceutica Nv Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004071449A2 (en) 2003-02-12 2004-08-26 Bristol-Myers Squibb Company Lactams as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US8481035B2 (en) 2004-04-27 2013-07-09 Northwestern University Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A
US20080146616A1 (en) * 2004-06-18 2008-06-19 Kristofer Olofsson Indoles Useful in the Treatment of Inflammation
DE602005009209D1 (de) 2004-06-18 2008-10-02 Biolipox Ab Zur behandlung von entzündungen geeignete indole
RU2007101703A (ru) * 2004-06-18 2008-07-27 Биолипокс Аб (Se) Индолы, полезные при лечении воспаления
JP2008514700A (ja) * 2004-09-28 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換されたジピペリジンｃｃｒ２アンタゴニスト
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ATE503741T1 (de) * 2005-01-14 2011-04-15 Chemocentryx Inc Heteroarylsulfonamide und ccr2
WO2006077412A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
CA2594878A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
CA2594777A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
EP1841766A1 (en) * 2005-01-19 2007-10-10 Biolipox AB Pyrrolopyridines useful in the treatment of inflammation
EP1838669A1 (en) * 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
ZA200705827B (en) 2005-01-19 2008-10-29 Biolipox Ab Indoles useful in the treatment of inflammation
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
JP5438975B2 (ja) 2006-01-06 2014-03-12 サノビオン ファーマシューティカルズ インク テトラロン系モノアミン再取り込み阻害剤
CA2648121C (en) 2006-03-31 2013-08-06 Sepracor Inc. Preparation of chiral amides and amines
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
BRPI0713216A2 (pt) * 2006-06-30 2012-12-04 Sepracor Inc inibiadores heterocìclos fundidos da d-aminoácido oxidase
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009007410A (es) * 2007-01-18 2009-09-09 Sepracor Inc Inhibidores de d-aminoacido oxidasa.
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
JP5306344B2 (ja) 2007-07-12 2013-10-02 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US10973809B2 (en) 2016-11-23 2021-04-13 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2537974A1 (fr) 1982-12-16 1984-06-22 Adir Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2565981B1 (fr) * 1984-06-15 1986-09-19 Adir Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4751231A (en) 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH10510538A (ja) * 1994-12-13 1998-10-13 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU711968B2 (en) 1995-04-04 1999-10-28 Encysive Pharmaceuticals Inc. Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JP2000516611A (ja) * 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体

Also Published As

Publication number Publication date
DE69903923T2 (de) 2003-07-10
KR20010040997A (ko) 2001-05-15
US6479527B1 (en) 2002-11-12
NZ505638A (en) 2002-09-27
CA2319082A1 (en) 1999-08-19
IL137876A0 (en) 2001-10-31
EP1056451B1 (en) 2002-11-13
NO20004091L (no) 2000-10-16
NO20004091D0 (no) 2000-08-16
CN1291094A (zh) 2001-04-11
GB9803228D0 (en) 1998-04-08
AU2432999A (en) 1999-08-30
JP2002502874A (ja) 2002-01-29
BR9907936A (pt) 2000-10-24
ATE227570T1 (de) 2002-11-15
WO1999040914A1 (en) 1999-08-19
EP1056451A1 (en) 2000-12-06
DE69903923D1 (de) 2002-12-19

Similar Documents

Publication Publication Date Title
GB9803228D0 (en) Chemical compounds
GB9803226D0 (en) Chemical compounds
GB9922173D0 (en) Chemical compounds
IL144483A0 (en) Chemical compounds
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE278673T1 (de) Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
BG106340A (en) Substituted oxoazaheterocyclyl compounds
BRPI0413233A (pt) novos compostos
EP1243583A4 (en) HETEROCYCLIC COMPOUNDS WITH SULFONAMIDE GROUPS
EP1184373A4 (en) TRICYCLIC CONNECTIONS
DK1109818T3 (da) Phosphoepoxider, fremgangsmåder til deres fremstilling og deres anvendelser
NO934760L (no) Arylsubstituerte heterosykliske forbindelser
DK0604355T3 (da) Arylsubstituerede heterocykliske forbindelser
AU2002359629A1 (en) Functionalized higher diamondoids
CA2440186A1 (en) Medicinal composition containing 1,3-thiazine derivative
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.